Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population

References

• AnderssonFBorgSJanssonSAThe costs of exacerbations in chronic obstructive pulmonary disease (COPD)Respir Med20029670070812243316
   PubMed Web of Science ®Google Scholar
• DalalAAChristensenLLiuFDirect costs of chronic obstructive pulmonary disease among managed care patientsInt J Chron Obstruct Pulmon Dis2010534134921037958
   PubMedGoogle Scholar
• AlbertsonTESchivoMZekiAAThe pharmacological approach to the elderly COPD patientDrugs Aging20133047950223580319
   PubMed Web of Science ®Google Scholar
• BhattNYWoodKLWhat defines abnormal lung function in older adults with chronic obstructive pulmonary disease?Drugs Aging20082571772818729545
   PubMed Web of Science ®Google Scholar
• ManninoDMWattGHoleDThe natural history of chronic obstructive pulmonary diseaseEur Respir J20062762764316507865
   PubMed Web of Science ®Google Scholar
• IncalziRAScarlataSPennazzaGChronic obstructive pulmonary disease in the elderlyEur J Intern Med20142532032824183233
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE groupRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• WedzichaJAThe heterogeneity of chronic obstructive pulmonary diseaseThorax20005563163210899236
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 Available from: http://www.goldcopd.orgAccessed January 15, 2014
   Google Scholar
• Daliresp [package insert]St Louis, MO, USAForest Pharmaceuticals, Inc2013
   Google Scholar
• CalverleyPMRabeKFGoehringUMRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet200937468569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trialsLancet200937469570319716961
   PubMed Web of Science ®Google Scholar
• LindenauerPKPekowPSLahtiMCAssociation of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary diseaseJAMA20103032359236720551406
   PubMed Web of Science ®Google Scholar
• MapelDWDutroMPMartonJPIdentifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims dataBMC Health Serv Res2011114321345188
   PubMed Web of Science ®Google Scholar
• HarveyRDrzayich-JankusDMosleyDUnited HealthcareRandom assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS^® Available from: http://www.mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdfAccessed February 11, 2015
   Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol1992456136191607900
   PubMed Web of Science ®Google Scholar
• KlabundeCNPotoskyALLeglerJMDevelopment of a comorbidity index using physician claims dataJ Clin Epidemiol2000531258126711146273
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trialLancet200536656357116099292
   PubMed Web of Science ®Google Scholar
• CalverleyPMSanchez-TorilFMcIvorAEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717615416117463412
   PubMed Web of Science ®Google Scholar
• WedzichaJARabeKFMartinezFJEfficacy of roflumilast in the COPD frequent exacerbator phenotypeChest20131431302131123117188
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• BergerMLMamdaniMAtkinsDGood research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part IValue Health2009121044105219793072
   PubMed Web of Science ®Google Scholar
• SunSXMarynchenkoMBanerjeeRCost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPDJ Med Econ20111480581521992217
   PubMedGoogle Scholar
• HertelNKotchieRWSamyshkinYCost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysisInt J Chron Obstruct Pulmon Dis2012718319922500119
   PubMed Web of Science ®Google Scholar
• SamyshkinYKotchieRWMörkACCost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United KingdomEur J Health Econ201415698223392624
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPvan NootenFELindemannMA 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary diseasePharmacoeconomics20072569571117640111
   PubMed Web of Science ®Google Scholar
• HawkinsNMPetrieMCJhundPSHeart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologyEur J Heart Fail20091113013919168510
   PubMed Web of Science ®Google Scholar
• ChatilaWMThomashowBMMinaiOAComorbidities in chronic obstructive pulmonary diseaseProc Am Thorac Soc2008554955518453370
   PubMedGoogle Scholar
• WanYShorrASunSImpact of roflumilast on exacerbations among patients with chronic obstructive pulmonary disease (COPD) in the real worldChest2013144745A
   Web of Science ®Google Scholar
• FuASunSHuangX30-Day readmission rate associated with roflumilast treatment among patients hospitalized for COPDChest2013144744A
   Web of Science ®Google Scholar
• JainRCaiQSunSXImpact of roflumilast treatment on health care utilizations and costs among COPD patients in a managed care populationJ Manag Care Pharm201420S36
   Google Scholar
• CalverleyPMMartinezFJFabbriLMDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538222791991
   PubMed Web of Science ®Google Scholar